Chronic Kidney Disease May Be Overestimated in the Elderly
Using a fixed estimated glomerular filtration rate threshold rather than an age-adapted definition may overestimate the burden of CKD
Urologic Disorders
Keytruda Gets Full Approval for First-Line Advanced Urothelial Carcinoma
The full approval was based on data from the confirmatory phase 3 KEYNOTE-361 trial, which included 1010 patients with locally advanced or metastatic urothelial carcinoma.
Korsuva Approved for Chronic Kidney Disease-Associated Pruritus
The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 clinical studies.
New Drug Product: Kerendia
This slideshow show drug information for Kerendia. Click here for the complete Kerendia monograph.
FDA: No Approval for Bladder Cancer Drug Vicineum
Vicineum is an investigational locally administered recombinant fusion protein that targets EpCAM antigens on the surface of tumor cells to deliver Pseudomonas Exotoxin A.
MPR Weekly Dose Podcast Episode 89
Big news on the COVID-19 vaccine booster dose. The CDC issues new recommendations on vaccines. What protection the Moderna vaccine offers after 6 months. A treatment approved for Pompe disease. And the FDA denies an application for a new roxadustat indication.
FDA Denies Approval of Roxadustat for Anemia in CKD
The FDA noted that the application could not be approved in its present form and had requested an additional clinical study be conducted.
Race-Free Equations for Glomerular Filtration Rate Compared
eGFRcys resulted in smallest change in CKD prevalence among Black adults compared with race-blended, race-removed equations
FDA Wants Another Study Before Deciding on Tenapanor Approval
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Study Supports Shorter Antibiotic Course for Afebrile Men With UTI
The double-blinded, placebo-controlled noninferiority study included a total of 272 afebrile men from 2 US Veterans Affairs medical centers.
